NCT06829524View on ClinicalTrials.gov

HANDLE-a Real World Study on Satralizumab in NMOSD

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions

Neuromyelitis Optica Spectrum Disorders (NMOSD)

Interventions

DRUG

Satralizumab

Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.

Trial Locations (1)

200040

Huashan Hospital, Shanghai

All Listed Sponsors

lead

Huashan Hospital

OTHER

NCT06829524 - HANDLE-a Real World Study on Satralizumab in NMOSD | Biotech Hunter | Biotech Hunter